Participating entities
Fight AIDS Foundation, IrsiCaixa AIDS Research Institute
Study of atorvastatin’s impact in reducing inflammation associated with ageing in HIV-infected patients aged over 60 years receiving treatment based on protease inhibitors compared with treatment based on raltegravir. The two study groups (protease-inhibitor and raltegravir) will receive atorvastatin for 48 weeks. After the switch in treatment, patients will be followed up within 1 month and then every 3 months. In addition to the usual viral load checks, CD4 counts and laboratory analyses, cell, plasma and serum samples will also be collected during the study in order to conduct molecular